Adaptimmune Therapeutics plc (NASDAQ: ADAP) Q1 2025 Earnings Call Transcript May 13, 2025 Adaptimmune Therapeutics plc beats ...

FTSE 100 futures are up 0.4%, lagging behind bigger moves higher for Europe and the US on optimism about trade progress ...

Q1 2025 Management View CEO Charlie Janac highlighted a record annual contract value plus royalties of $66.8 million for the first quarter, with $2.7 million in non-GAAP positive free cash flow, and ...